By Anna Rose Welch, Editor, Biosimilar Development
Today, many companies are focusing on how they can tackle the regulatory challenges and get a biosimilar approved in the United States. However, there is one important question that, surprisingly, can get overlooked: How can a company in the biosimilar space compete and actually make money doing it?
By Eric Langer, President and Managing Partner, BioPlan Associates, Inc.
One of the most important trends to emerge from preliminary results of this year’s survey is the increased attention paid to continuous bioprocessing. Integrated, broad upstream and downstream technologies remain to be developed and commercialized. Despite this lack of viable options, there is a groundswell of enthusiasm for the concept.
By Dr. Nick Hutchinson, Contributor
Despite the fact continuous biomanufacturing methods are receiving considerable industry attention and interest, it’s hard to identify a CMO that is attempting to emphasize its position as an expert in this field. What might the causes be that would lead to a discrepancy between apparent demand for fully continuous capacity and the supply from biomanufacturing CMOs?